E-Mail
Mutations in two genetic regions in dogs explain over one third of the risk of developing an aggressive form of hematological cancer, according to a study led by Jacquelyn Evans and Elaine Ostrander at the National Human Genome Research Institute in Maryland, USA and colleagues. The study, which combined multiple sequencing techniques to investigate histiocytic sarcoma in retriever dogs, publishes May 13 in the open-access journal
PLOS Genetics.
Histiocytic sarcoma is an aggressive cancer of immune cells, and although extremely rare in humans, it affects around one-in-five flat-coated retrievers. Genome-wide association surveys of 177 affected and 132 unaffected flat-coated retrievers identified two loci on chromosomes 5 and 19 of the canine genome associated with histiocytic sarcoma. Whole genome, transcriptome, and chromatin immunoprecipitation (CHiP) sequence data revealed that the CFA5 locus contains mutations near a known tumor-suppressor gene, PIK3R6. CFA5 also
Colorado State University studying vaccine to help prevent cancer in dogs
thedenverchannel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedenverchannel.com Daily Mail and Mail on Sunday newspapers.
Colorado cancer doctors have a pack mentality
gazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazette.com Daily Mail and Mail on Sunday newspapers.
Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care
March 16, 2021 08:00 ET | Source: Sensus Healthcare, Inc. Sensus Healthcare, Inc.
Best-in-class localization features of SRT-100 enable new radiation therapy options in veterinary settings BOCA RATON, Fla, March 16, 2021 (GLOBE NEWSWIRE) Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today that the first canine patient was successfully treated with the company’s SRT-100™ system. SRT-100 systems utilize Sensus Healthcare’s proprietary low-energy x-ray technology known as superficial radiation therapy (SRT) that enables radiation therapy to target harder-to-reach lesions, such as those often found in animal patients.